Agenus Inc (NAS:AGEN)
$ 2.81 0.06 (2.18%) Market Cap: 64.93 Mil Enterprise Value: 119.07 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Agenus Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 12:40PM GMT
Release Date Price: $101.66 (-2.26%)
Timor Ivannikov
Raymond James Financial - Analyst

Hello, everyone. My name is Timor Ivannikov, and I am a biotech analyst at Raymond James. Today, we are pleased to host Agenus at our annual Human Health Innovation Conference. Presenting on behalf of Agenus, we welcome President and COO, Jennifer Buell; and we also have Director of IR, Jan Medina. Agenus is a clinical-stage immuno-oncology biotech company. (Conference Instructions). So thank you, everyone, for joining us today. And please go ahead, Jennifer.

Jennifer Buell
Agenus Inc. - President & COO

Timor, thanks very much for the opportunity to be here. I appreciate it. And thank you to the Raymond James group. We are really pleased to present Agenus. I'm going to go ahead and just share a couple of slides, and I'll tell you -- I'm going to focus really on a couple of core points about Agenus -- what we are doing, who we are, and where we are going. Can you see my screen okay, Timor?

Timor Ivannikov
Raymond James Financial - Analyst

Yes, yes, we see it.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot